4/1
01:32 pm
axsm
Why Shares of Axsome Therapeutics Slumped Today [Yahoo! Finance]
Low
Report
Why Shares of Axsome Therapeutics Slumped Today [Yahoo! Finance]
4/1
09:04 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
4/1
07:12 am
axsm
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) [Yahoo! Finance]
Low
Report
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) [Yahoo! Finance]
4/1
07:00 am
axsm
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
Low
Report
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
3/27
08:57 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Mizuho from $212.00 to $216.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Mizuho from $212.00 to $216.00. They now have an "outperform" rating on the stock.
3/26
12:32 pm
axsm
Bayer gains cancer drug from China's Puhe; Axsome gets mixed ADHD data [Yahoo! Finance]
Low
Report
Bayer gains cancer drug from China's Puhe; Axsome gets mixed ADHD data [Yahoo! Finance]
3/25
01:09 pm
axsm
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. [Yahoo! Finance]
Low
Report
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. [Yahoo! Finance]
3/25
07:08 am
axsm
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint [Yahoo! Finance]
Medium
Report
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint [Yahoo! Finance]
3/25
07:00 am
axsm
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
Medium
Report
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
3/6
02:26 pm
axsm
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Low
Report
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
3/6
08:12 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
3/5
07:42 am
axsm
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA [Yahoo! Finance]
Low
Report
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA [Yahoo! Finance]
3/5
07:00 am
axsm
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Low
Report
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
3/3
12:41 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
3/3
08:10 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $132.00 to $160.00. They now have an "outperform" rating on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $132.00 to $160.00. They now have an "outperform" rating on the stock.
3/3
07:42 am
axsm
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission [Yahoo! Finance]
Low
Report
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission [Yahoo! Finance]
3/3
07:00 am
axsm
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Low
Report
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
2/27
08:36 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Morgan Stanley from $125.00 to $190.00. They now have an "overweight" rating on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Morgan Stanley from $125.00 to $190.00. They now have an "overweight" rating on the stock.
2/26
11:36 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Mizuho from $195.00 to $212.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Mizuho from $195.00 to $212.00. They now have an "outperform" rating on the stock.
2/26
07:00 am
axsm
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Axsome Therapeutics to Participate in Upcoming Investor Conferences
2/24
07:09 am
axsm
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors [Yahoo! Finance]
Medium
Report
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors [Yahoo! Finance]
2/24
07:00 am
axsm
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
Medium
Report
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
2/22
03:30 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was given a new $132.00 price target on by analysts at Robert W. Baird.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was given a new $132.00 price target on by analysts at Robert W. Baird.
2/21
12:21 pm
axsm
Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 [Yahoo! Finance]
Low
Report
Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 [Yahoo! Finance]
2/20
08:13 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at HC Wainwright from $190.00 to $200.00. They now have a "buy" rating on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at HC Wainwright from $190.00 to $200.00. They now have a "buy" rating on the stock.